Hydroquinone-induced miR-122 down-regulation elicits ADAM17 up-regulation, leading to increased soluble TNF-A production in human leukemia cells with expressed Bcr/Abl

Biochemical Pharmacology

Volumn 86, Issue 5, 2013, Pages 620-631

  Chen, Ying Jung ^a   Chang, Long Sen ^a,b  

^a NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

ADAM17; AP 1; Hydroquinone; JNK; MiR 122; P38 MAPK; TNF

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BCR ABL PROTEIN; BETA ACTIN; HYDROQUINONE; MESSENGER RNA; MICRORNA 122; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ARTICLE; CELL STRAIN K 562; CELL SURFACE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA PURIFICATION; DNA TRANSFECTION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; ONCOGENE C FOS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION; RNA INTERFERENCE; UPREGULATION;

EID: 84884907687     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.06.009     Document Type: Article

References (49)

1. Szlosarek PW, Balkwill FR. Tumor necrosis factor a: a potential target for the therapy of solid tumours. Lancet Oncol 2003;4:565-73. (Pubitemid 38351714)
2. Wajant H. Death receptors. Essays Biochem 2003;39:53-71. (Pubitemid 37457071)
3. Guicciardi ME, Gores GJ. Life and death by death receptors. FASEB J 2009;23:1625-37.
4. Faustman D, Davis M. TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov 2010;9:482-93.
5. Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci 2007;98:621-8. (Pubitemid 46563436)
6. Deleault KM, Skinner SJ, Brooks SA. Tristetraprolin regulates TNF TNF-A mRNA stability via a proteasome dependent mechanism involving the combined action of the ERK and p38 pathways. Mol Immunol 2008;45:13-24. (Pubitemid 47331659)
7. Carballo E, Blackshear PJ. Roles of tumor necrosis factor-A receptor subtypes in the pathogenesis of the tristetraprolin-deficiency syndrome. Blood 2001;98:2389-95.
8. Qiu LQ, Stumpo DJ, Blackshear PJ. Myeloid-specific tristetraprolin deficiency in mice results in extreme lipopolysaccharide sensitivity in an otherwise mini-mal phenotype. J Immunol 2012;188:5150-9.
9. Ramakrishnan A, Deeg HJ. A novel role for the marrow microenvironment in initiating and sustaining hematopoietic disease. Expert Opin Biol Ther 2009;9:21-8.
10. Marcondes AM, Ramakrishnan A, Deeg HJ. Myeloid malignancies and the marrow microenvironment: some recent studies in patients with MDS. Curr Cancer Ther Rev 2009;5:310-4.
11. Cachaco AS, Carvalho T, Santos AC, Igreja C, Fragoso R, Osorio C, et al. TNF-A regulates the effects of irradiation in the mouse bone marrow microenviron-ment. PloS One 2010;5:e8980.
12. Fleischman AG, Aichberger KJ, Luty SB, Bumm TG, Petersen CL, Doratotaj S, et al. TNF-A facilitates clonal expansion of JAK2V617F positive cells in mye-loproliferative neoplasms. Blood 2011;118:6392-8.
13. Irons RD. Quinones as toxic metabolites of benzene. J Toxicol Environ Health A 1985;16:673-8. (Pubitemid 16160274)
14. Ross D. Metabolic basis of benzene toxicity. Eur J Haematol 1996;60(Suppl.): 111-8.
15. Ross D. The role of metabolism and specific metabolites in benzene induced toxicity: evidence and issues. J Toxicol Environ Health A 2000;61:357-62.
16. Hayes RB, Yin S, Rothman N, Dosemici M, Li G, Travis LT, et al. Benzene and lymphohematopoietic maignancies in China. J Toxicol Environ Health A 2000;61:419-32.
17. Hebeda CB, Pinedo FJ, Vinolo MA, Curi R, Farsky SH. Hydroquinone stimulates inflammatory functions in microvascular endothelial cells via NF-kB nuclear activation. Basic Clin Pharmacol Toxicol 2011;109:372-80.
18. Gillis B, Gavin IM, Arbieva Z, King ST, Jayaraman S, Prabhakar BS. Identification of human cell responses to benzene and benzene metabolites. Genomics 2007;90:324-33. (Pubitemid 47176335)
19. Shimada AL, Lino-Dos-Santos-Franco A, Bolonheis SM, Nakasato A, Damazo AS, Tavares-de-Lima W, et al. In vivo hydroquinone exposure causes tracheal hyperresponsiveness due to TNF secretion by epithelial cells. Toxicol Lett 2012;211:10-7.
20. Hazel BA, O'Connor A, Niculescu R, Kalf GF. Induction of granulocytic differ-entiation in a mouse model by benzene and hydroquinone. Environ Health Perspect 1996;104(Suppl. 6):1257-64. (Pubitemid 27046152)
21. Chen YJ, Chang LS. Arecoline-induced death of human leukemia K562 cells is associated with surface up-modulation of TNFR2. J Cell Physiol 2012;227:2240-51.
22. Liu WH, Chang LS. Suppression of ADAM17-mediated Lyn/Akt pathways induces apoptosis of human leukemia U937 cells: Bungarus multicinctus protease inhibitor-like protein-1 uncovers the cytotoxic mechanism. J Biol Chem 2010;285:30506-15.
23. Liu WH, Chang LS. Fas/FasL-dependent, and -independent activation of cas-pase-8 in doxorubicin-treated human breast cancer MCF-7 cells: ADAM10 down-regulation activates Fas/FasL signaling pathway. Int J Biochem Cell Biol 2011;43:1708-19.
24. Seals DF, Courtneidge SA. The ADAMs family of metalloproteinases: multi-domain proteins with multiple functions. Genes Dev 2003;17:7-30. (Pubitemid 36062504)
25. Armanious H, Gelebart P, Anand M, Belch A, Lai R. Constitutive activation of metalloproteinase ADAM10 in mantle cell lymphoma promotes cell growth and activates the TNF-A/NFkB pathway. Blood 2011;117:6237-46.
26. Arribas J, Esselens C. ADAM17 as a therapeutic target in multiple diseases. Curr Pharm Des 2009;15:2319-35.
27. Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, Chen CM, et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepa-tocellular carcinoma. Hepatology 2009;49:1571-82.
28. Gregersen LH, Jacobsen AB, Frankel LB, Wen J, Krogh A, Lund AH. MicroRNA- 145 targets YES and STAT1 in colon cancer cells. PLoS One 2010;5:e8836.
29. Sachdeva M, Mo YY. miR-145-mediated suppression of cell growth, invasion and metastasis. Am J Transl Res 2010;2:170-80.
30. Xu K, Liang X, Shen K, Sun L, Cui D, Zhao Y, et al. MiR-222 modulate multidrug resistance in human colorectal carcinoma by down-regulating ADAM-17. Exp Cell Res 2012;318:2168-77.
31. Felli N, Fontana L, Pelosi E, Botta R, Bonci D, Facchiano F, et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci USA 2005;102:18081-86. (Pubitemid 41798505)
32. Gu TJ, Yi X, Zhao XW, Zhao Y, Yin JQ. Alu-directed transcriptional regulation of some novel miRNAs. BMC Genom 2009;10:563.
33. Zheng JH, Pyatt DW, Gross SA, Le AT, Kerzic PJ, Irons RD. Hydroquinone modulates the GM-CSF signaling pathway in TF-1 cells. Leukemia 2004;18:1296-304. (Pubitemid 39023141)
34. Kim YJ, Woo HD, Kim BM, Lee YJ, Kang SJ, Cho YH, et al. Risk assessment of hydroquinone: differential responses of cell growth and lethality correlated to hydroquinone concentration. J Toxicol Environ Health A 2009;72:1272-8.
35. Soond SM, Everson B, Riches DWH, Murphy G. ERK-mediated phosphorylation of Thr735 in TNFa-converting enzyme and its potential role in TACE protein trafficking. J Cell Sci 2005;118:2371-80. (Pubitemid 40873077)
36. Krishna M, Narang H. The complexity of mitogen-Activated protein kinases (MAPKs) made simple. Cell Mol Life Sci 2008;65:3525-44.
37. Bai S, Nasser MW, Wang B, Hsu SH, Datta J, Kutay H, et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensi-tizes these cells to sorafenib. J Biol Chem 2009;284:32015-27.
38. Holst LM, Kaczkowski B, Gniadecki R. Reproducible pattern of microRNA in normal human skin. Exp Dermatol 2010;19:e201-5.
39. Manfe V, Biskup E, Rosbjerg A, Kamstrup M, Skov AG, Lerche CM, et al. miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma. PLoS One 2012;7:e29541.
40. Peter ME. Targeting of mRNAs by multiple miRNAs: the next step. Oncogene 2010;29:2161-4.
41. Thomson DW, Bracken CP, Goodall GJ. Experimental strategies for microRNA target identification. Nucleic Acids Res 2011;39:6845-53.
42. Kedde M, Strasser MJ, Boldajipour B, Oude Vrielink JA, Slanchev K, le Sage C, et al. RNA-binding protein Dnd1 inhibits microRNA access to target mRNA. Cell 2007;131:1273-86.
43. Masuda K, Marasa B, Martindale JL, Halushka MK, Gorospe M. Tissue- and age-dependent expression of RNA-binding proteins that influence mRNA turnover and translation. Aging (Albany NY) 2009;1:681-98.
44. San Jose-Eneriz E, Roman-Gomez J, Jimenez-Velasco A, Garate L, Martin V, Cordeu L, et al. MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations. Mol Cancer 2009;8:69.
45. Machova Polakova K, Lopotova T, Klamova H, Burda P, Trneny M, Stopka T, et al. Expression patterns of microRNAs associated with CML phases and their disease related targets. Mol Cancer 2011;10:41.
46. Liu WH, Chou WM. Chang LS. p38 MAPK/PP2Aca/TTP pathway on the con-nection of TNF-A and caspases activation on hydroquinone-induced apoptosis. Carcinogenesis 2013;34:818-27.
47. Salesse S, Verfaillie CM. BCR/ABL-mediated increased expression of multiple known and novel genes that may contribute to the pathogenesis of chronic myelogenous leukemia. Mol Cancer Ther 2003;2:173-82.
48. Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 2012;119:1501-10.
49. Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 2010;120:2254-64.